about
Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinomaKi67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.DNA damage response markers are differentially expressed in BRCA-mutated breast cancersConstruction of tissue microarrays from core needle biopsies - a systematic literature review.Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerClinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.Clinical utility of reverse phase protein array for molecular classification of breast cancer.Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer.Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.An approach to the diagnosis of spindle cell lesions of the breast.Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.RECQL4 helicase has oncogenic potential in sporadic breast cancers.The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy.Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.Further evidence to support bimodality of oestrogen receptor expression in breast cancer.FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancerThe prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast.The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.Pleomorphic adenoma-like tumour of the breast.Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
P50
Q33593895-A94CD56C-54C3-476B-A3DA-4ADE2210467FQ33843751-7D0499AB-6E9E-41A9-BE88-6AFD0A6F56CBQ35131267-BA6824A9-D569-433C-9FC1-1E05242F5EDFQ35743491-81DC3AF6-B358-49C1-B8B8-E5A84523608DQ36393082-9A3E829B-2432-4C4C-8F53-FC123F56B529Q36468823-44570204-67E2-486B-A010-EA16F15CD285Q36908377-C2B05E88-B56F-43A8-8DD2-3FF9A1C08183Q37046332-3B57B555-3125-4B54-B38A-760C59BBF4D9Q37174700-8DEF5499-448C-4A31-BCC4-55E1FE29D011Q37419375-C2881134-2EC0-4BF1-B4A7-696470CFF8E4Q38383140-41FA01C2-CA9B-4C34-8BE9-32683D8D8E5BQ38383534-9E8F5914-9303-4825-B757-1F8BD54BF372Q38391935-88A597D5-3402-4A63-8765-837C703A7F80Q38578695-0649C0CE-4248-4114-B574-9783F8E6E138Q38614205-9848110F-97E9-4992-AE33-2FC434C95C04Q38696784-79121F76-DDC8-4CA3-82C1-EA5F35A47937Q38731624-18B0A36C-A0C6-422B-80E4-797F91FCB60FQ38805436-64C536EE-C608-464C-BAF4-B51AC0DB8AA5Q38809989-7BD3F30B-D112-4FA4-9D46-B121F35868C1Q38864173-697F107F-4BE0-4E6C-9FC0-E2B6A216CD2EQ38888197-AD8245B5-14B4-48DE-B4C0-87C3D0445A99Q38910511-50B09544-0A18-44EA-918B-44F61F4F24BDQ39060237-F926661A-7EFE-4B88-8DF3-6655D159DC31Q39371309-F587D968-520F-46AC-83E8-E06A1A667C75Q39588969-21DE8592-B5FB-425F-BA32-DD517FE1A8BEQ39682405-EAAE441A-6439-46DF-9208-2678051265B2Q39880360-419A921B-2348-44B6-98F5-81DB08F2D388Q39974818-C49FBC00-A8C3-43A1-A225-AD79E535D95DQ40348126-EA659E96-6AE7-4300-978B-8BDD0A83CF28Q40962515-ADD9113D-D008-4B94-AC31-F4589620B605Q41137374-73365FAF-3742-44B6-963A-E21E041E80E7Q42450895-00269FFF-00FA-46D6-905E-582F3D5728D7Q42456749-6CB452B9-2174-433C-B96F-8F96067BF7BCQ42458899-B5D47A3D-2785-4AB4-9C73-61974FF67A08Q42478662-15356891-9B3F-43CB-BD1C-72673311D386Q42496885-4D886AFE-5F3A-4406-8399-0EB383A1ED84Q42516415-FA1BCB5D-F133-4C6C-ADC5-1342FFEF8E31Q43285080-29220333-E915-44BD-B1ED-9A10B4BD6C3AQ43722435-083D9693-3028-4D44-BE7E-320FF9420D56Q45249576-3CEAC329-3A73-42EA-9981-C0F50A1AC01D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mohammed A Aleskandarany
@ast
Mohammed A Aleskandarany
@en
Mohammed A Aleskandarany
@es
Mohammed A Aleskandarany
@nl
type
label
Mohammed A Aleskandarany
@ast
Mohammed A Aleskandarany
@en
Mohammed A Aleskandarany
@es
Mohammed A Aleskandarany
@nl
prefLabel
Mohammed A Aleskandarany
@ast
Mohammed A Aleskandarany
@en
Mohammed A Aleskandarany
@es
Mohammed A Aleskandarany
@nl
P106
P1153
24173186400
P31
P496
0000-0001-5538-5946